CR20240461A - Inhibidores de parp1 tricíclicos y usos de estos - Google Patents

Inhibidores de parp1 tricíclicos y usos de estos

Info

Publication number
CR20240461A
CR20240461A CR20240461A CR20240461A CR20240461A CR 20240461 A CR20240461 A CR 20240461A CR 20240461 A CR20240461 A CR 20240461A CR 20240461 A CR20240461 A CR 20240461A CR 20240461 A CR20240461 A CR 20240461A
Authority
CR
Costa Rica
Prior art keywords
tricyclic
parp1 inhibitors
inhibitors
parp1
compositions
Prior art date
Application number
CR20240461A
Other languages
English (en)
Spanish (es)
Inventor
Porino Jinjo Va
Joseph Robert Pinchman
Qing Dong
Robert L Hoffman
Stephen W Kaldor
Original Assignee
Xinthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinthera Inc filed Critical Xinthera Inc
Publication of CR20240461A publication Critical patent/CR20240461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR20240461A 2022-04-28 2023-04-27 Inhibidores de parp1 tricíclicos y usos de estos CR20240461A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336078P 2022-04-28 2022-04-28
US202263381482P 2022-10-28 2022-10-28
PCT/US2023/020235 WO2023212219A1 (en) 2022-04-28 2023-04-27 Tricyclic parp1 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CR20240461A true CR20240461A (es) 2024-12-09

Family

ID=88420972

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240461A CR20240461A (es) 2022-04-28 2023-04-27 Inhibidores de parp1 tricíclicos y usos de estos

Country Status (25)

Country Link
US (3) US11795173B1 (cg-RX-API-DMAC7.html)
EP (3) EP4497438B1 (cg-RX-API-DMAC7.html)
JP (2) JP7728989B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260004578A (cg-RX-API-DMAC7.html)
CN (1) CN119173516A (cg-RX-API-DMAC7.html)
AU (2) AU2023259236B2 (cg-RX-API-DMAC7.html)
CA (1) CA3250945A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024003262A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014603A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240461A (cg-RX-API-DMAC7.html)
DK (2) DK4497438T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000218A (cg-RX-API-DMAC7.html)
ES (2) ES3050217T3 (cg-RX-API-DMAC7.html)
FI (2) FI4497438T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20250969T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072274T2 (cg-RX-API-DMAC7.html)
IL (1) IL316278A (cg-RX-API-DMAC7.html)
LT (2) LT4497438T (cg-RX-API-DMAC7.html)
MX (2) MX2025008920A (cg-RX-API-DMAC7.html)
NZ (1) NZ815323A (cg-RX-API-DMAC7.html)
PL (2) PL4355749T3 (cg-RX-API-DMAC7.html)
PT (2) PT4497438T (cg-RX-API-DMAC7.html)
SI (2) SI4497438T1 (cg-RX-API-DMAC7.html)
TW (2) TW202540112A (cg-RX-API-DMAC7.html)
WO (1) WO2023212219A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
AU2023229992A1 (en) * 2022-03-11 2024-10-10 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and the use thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
CN117263943B (zh) * 2022-09-09 2026-06-02 轩竹生物科技股份有限公司 聚(adp核糖)聚合酶选择性抑制剂
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
TW202525808A (zh) * 2023-09-13 2025-07-01 大陸商上海瑛派藥業有限公司 用作parp1抑制劑的化合物、其用途及包含其之組合物
AU2024359243A1 (en) * 2023-10-09 2026-04-23 Incyte Corporation Processes for preparing kras inhibitors
WO2026142998A1 (en) 2024-12-24 2026-07-02 Gilead Sciences, Inc. Crystalline forms of a parp1 inhibitor

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
EP2389379A1 (en) 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
CN102647904A (zh) 2009-09-16 2012-08-22 赛林药物股份有限公司 新型三环蛋白激酶调节剂
EA028506B1 (ru) 2012-10-26 2017-11-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 4-карбоксамидо-изоиндолинона в качестве селективных ингибиторов parp-1, способ их получения и применение
CN104370898A (zh) 2013-08-14 2015-02-25 黄传满 咪唑并[1,2-a]吡啶类化合物及其制备方法和用途
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ(lsd1)およびヒストンデアセチラーゼ(hdac)の阻害剤
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
PT3312177T (pt) 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
CN107922409A (zh) 2015-08-17 2018-04-17 鲁宾有限公司 作为parp抑制剂的杂芳基衍生物
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
IL283127B2 (en) 2018-11-14 2026-06-01 Smilebiotek Zhuhai Ltd Animal models, screening methods, and treatment methods for intraocular diseases or disorders
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
JP7512380B2 (ja) 2019-10-30 2024-07-08 ディグムバイオ.インコーポレイテッド イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ(adp-リボース)ポリメラーゼ-1(parp-1)関連疾患の予防又は治療用薬学的組成物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022222921A1 (zh) 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 含哌嗪结构的parp抑制剂、其制备方法及医药用途
CN116601148A (zh) 2021-04-23 2023-08-15 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN116710433B (zh) 2021-04-23 2026-05-05 康百达(四川)生物医药科技有限公司 一种选择性parp1抑制剂及其应用
CN116867783B (zh) 2021-04-23 2026-08-07 康百达(四川)生物医药科技有限公司 吡啶衍生物及其在医药上的应用
TW202304911A (zh) 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2022228387A1 (en) 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
AU2022280845A1 (en) 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
CN115403595A (zh) 2021-05-27 2022-11-29 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
JP2024522736A (ja) 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023036285A1 (zh) 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051716A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
WO2023051812A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
WO2023051807A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
WO2023061406A1 (zh) 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
CA3238572A1 (en) 2021-11-19 2023-05-25 Jing Zhang Selective parp1 inhibitor and application thereof
CN116143776A (zh) 2021-11-22 2023-05-23 南京圣和药业股份有限公司 Parp1抑制剂及其应用
CN118382624A (zh) 2021-12-17 2024-07-23 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
WO2023133413A1 (en) 2022-01-07 2023-07-13 Slap Pharmaceuticals Llc Multicyclic compounds
US20250221987A1 (en) 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
CN118434725B (zh) 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CN116535401A (zh) 2022-01-25 2023-08-04 南京圣和药业股份有限公司 新的parp1抑制剂及其应用
WO2023143236A1 (zh) 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023147009A1 (en) 2022-01-27 2023-08-03 The Johns Hopkins University Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks
CA3246093A1 (en) 2022-01-27 2023-08-03 Xinthera, Inc. PARP1 INHIBITORS AND THEIR USES
US20250177359A1 (en) 2022-01-28 2025-06-05 Oulun Yliopisto Compounds for use in the treatment of cancer and inflammatory conditions
AU2023212785A1 (en) 2022-01-28 2024-08-15 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR102983934B1 (ko) 2022-01-28 2026-06-29 경북대학교 산학협력단 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물
JP2025508714A (ja) 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物
AU2023229992A1 (en) 2022-03-11 2024-10-10 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and the use thereof
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4514795A4 (en) 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
WO2023207284A1 (en) 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
EP4524142A4 (en) 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
AU2023275808A1 (en) 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
US20250346573A1 (en) 2022-06-02 2025-11-13 Chengdu Easton Biopharmaceuticals Co., Ltd. Azaquinolinone derivative, preparation method therefor and use thereof
CN117447449A (zh) 2022-07-13 2024-01-26 南京圣和药业股份有限公司 Parp1抑制剂及其应用
CN115232129B (zh) 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041643A1 (zh) 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
WO2024050370A1 (en) 2022-08-30 2024-03-07 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
WO2024046420A1 (zh) 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
CN117658983A (zh) 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
TW202416977A (zh) 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
CN118139862A (zh) 2022-09-30 2024-06-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
US20240174669A1 (en) 2022-10-06 2024-05-30 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083201A1 (zh) 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
WO2024083218A1 (zh) 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
CN117946074A (zh) 2022-10-20 2024-04-30 上海海和药物研究开发股份有限公司 具有parp1抑制活性的化合物及其用途
CN120035592A (zh) 2022-10-20 2025-05-23 成都赜灵生物医药科技有限公司 并杂环类氘代化合物及其用途
WO2024099364A2 (en) 2022-11-09 2024-05-16 Laekna Therapeutics Shanghai Co., Ltd. Fused multicyclic compounds and their use as parp1 inhibitors
AU2023378452A1 (en) 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
KR20250103773A (ko) 2022-11-23 2025-07-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법
CN118084916A (zh) 2022-11-25 2024-05-28 成都赜灵生物医药科技有限公司 三并杂环类化合物及其用途
EP4688769A1 (en) 2023-03-24 2026-02-11 Xinthera, Inc. Crystalline forms of an azetidine parp1 inhibitor
CN116987066B (zh) 2023-06-20 2025-07-25 四川大学 一种嘧啶类化合物及其制备方法和应用
CN117017962A (zh) 2023-08-23 2023-11-10 复旦大学附属肿瘤医院 一种hdaci抑制剂在制备治疗卵巢癌药物中的用途

Also Published As

Publication number Publication date
KR20260004578A (ko) 2026-01-08
MX2024013195A (es) 2024-12-06
SI4497438T1 (sl) 2025-12-31
KR102903399B1 (ko) 2025-12-24
TW202540112A (zh) 2025-10-16
US20240109904A1 (en) 2024-04-04
CL2025002554A1 (es) 2025-12-05
EP4497438A3 (en) 2025-02-19
HUE072274T2 (hu) 2025-11-28
US20230348473A1 (en) 2023-11-02
MX2025008920A (es) 2025-09-02
EP4355749A1 (en) 2024-04-24
JP7728989B2 (ja) 2025-08-25
FI4355749T3 (fi) 2025-07-23
JP2025161856A (ja) 2025-10-24
PT4355749T (pt) 2025-08-13
US12006322B2 (en) 2024-06-11
EP4497438B1 (en) 2025-09-03
EP4497438A2 (en) 2025-01-29
US12421241B2 (en) 2025-09-23
JP2025514189A (ja) 2025-05-02
EP4355749B1 (en) 2025-06-04
SI4355749T1 (sl) 2025-10-30
DK4355749T3 (da) 2025-06-30
HRP20250969T1 (hr) 2025-10-10
DK4497438T3 (da) 2025-09-29
NZ815323A (en) 2025-12-19
WO2023212219A1 (en) 2023-11-02
DOP2024000218A (es) 2024-11-29
PT4497438T (pt) 2025-10-31
IL316278A (en) 2024-12-01
US11795173B1 (en) 2023-10-24
EP4620472A2 (en) 2025-09-24
LT4497438T (lt) 2025-11-25
AU2023259236A1 (en) 2024-10-24
ES3050217T3 (en) 2025-12-19
TWI891000B (zh) 2025-07-21
US20240400569A1 (en) 2024-12-05
PL4355749T3 (pl) 2025-09-22
LT4355749T (lt) 2025-08-25
EP4620472A3 (en) 2025-10-01
KR20240172235A (ko) 2024-12-09
AU2023259236B2 (en) 2025-01-09
CO2024014603A2 (es) 2024-12-09
CA3250945A1 (en) 2023-11-02
AU2025202495A1 (en) 2025-05-01
TW202400596A (zh) 2024-01-01
FI4497438T3 (fi) 2025-10-20
CN119173516A (zh) 2024-12-20
ES3038967T3 (en) 2025-10-16
EP4355749A4 (en) 2024-11-13
CL2024003262A1 (es) 2025-03-14
HRP20251173T1 (hr) 2025-11-21
PL4497438T3 (pl) 2026-01-26

Similar Documents

Publication Publication Date Title
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
CR20240144A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
PH12022552739A1 (en) Fused tricyclic kras inhibitors
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
ZA202204941B (en) Cd73 inhibitors
MX2023002507A (es) Inhibidores de cd73.
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
MX2024014262A (es) Inhibidores de parg
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2025007174A (es) Dispersion solida de un inhibidor de her2
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2025002424A (es) Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2025000659A (es) Compuestos de imidazopiridina, preparacion de los mismos y usos terapeuticos de los mismos
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
MX2024011197A (es) Combinaciones que comprenden inhibidores de metap2 para el tratamiento de cancer.
MX2022010299A (es) Derivados macrocíclicos de indol como inhibidores de mcl-1.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
MX2024005928A (es) 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1.